Free Communications - Methylation 1: From risk to triage

5:15 PM • FC 14-01 • HPV E4 expression and DNA hypermethylation of CADM1, MAL, and MIR124-2 genes in cervical cancer and precursor lesions > C. Chris MEIJER 5:24 PM • FC 14-02 • FAM19A4/MIR124-2 methylation analysis in the pobascam trial with long-term follow-up > S. Stèfanie Dick 5:33 PM • FC 14-03 • Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV focal cervical cancer screening trial > A. Attila LORINCZ 5:42 PM • FC 14-04 • DNA methylation panel for the triage of HPV positive women in a primary screening population > S. Stephen Reynolds 5:51 PM • FC 14-05 • The performance of FAM19A4/MIR124-2 methylation analysis as a triage test for HPV-screen positive women and as a rule out test for cervical cancer > D. Daniëlle HEIDEMAN 6:00 PM • FC 14-06 • Methylation can predict progression of CIN2 > K. Karolina Louvanto 6:09 PM • FC 14-07 • Methylation biomarkers for triage of women below the age of 30 with HPV positive SurePath collected samples > H. Helle Pedersen 6:18 PM • FC 14-08 • Methylation analysis of host cell genes in first-void urine to detect cervical precancer lesions in a referral population > S. Severien Van Keer 6:27 PM • FC 14-09 • Differentiating cervical pre-cancer from invasive cancer with the S5 DNA methylation classifier > C. Cristiana Banila 6:36 PM • FC 14-10 • DNA methylation analysis in urine to detect cervical cancer and precancer > R. Rianne Van Den Helder